




The first Spanish biomarker discovery company with dual R&D pipeline in Diagnostic and therapy for oncology and neurodegenerative diseases

Oryzon Technology Assets



- ✓ Functional Genomics Platform for Biomedical Projects:
 - biomarker/target discovery programs
 - ✓ Design of specific microarrays
 - ✓ Toxicogenomics
 - ✓ Pharmacogenetics

- ✓ Fragment based approach (NMR and X-Ray Crystallography) combined with medicinal chemistry and computational methods for the identification and optimization of novel chemical series


Oryzon wants to enlarge and consolidate specialized services to the pharma and biotech industry.

Oryzon Pipeline

Human DIAGNOSTICS Strengths

- Central Lab certified for Human Diagnosis Tests in 2010
- Launching of two products (DNAchips) foreseen in 2011

In vitro Diagnostics Pipeline




- Peripheral Tissue / Blood-based
- Tissue-based
- ★ In final negotiations. These are ready to launch products or well advanced discovery projects from other companies which can make their way to the market in a short time


Strategic Partnerships and Goals

- Ready to partner our internal programs of new targets/ new mechanisms with the pharma industry focused on identifying epigenetic molecules in oncology and neurodegeneration
- Oryzon is open to partner /develop other programs of interest for the pharma industry where we can add differential value

Small Molecule Pipeline



mAb Pipeline



- Oryzon has Licensed Human Antibody Phage Display Technology for Discovery of Novel Therapeutics From Dyax Corp.
- Oryzon is now the only Spanish company with FTO in the commercial development of mAb's

- World class R&D facilities in the Barcelona Area
- International team of 60 scientist
- Looking for strategic partnerships
- Incorporated in 2000 and Venture Backed from 2003

ISO9001
Certified since 2007 for all company processes

